Antithrombotic activities of aqueous extract from Radix Ophiopogon japonicus and its two constituents.

To provide further pharmacological evidence for its clinical use in thrombotic diseases, the antithrombotic activities of the aqueous extract of Radix Ophiopogon japonicus (ROJ-ext) were studied in mouse and rat models. The results showed that ROJ-ext remarkably decreased length of tail thrombus in mice at 48 h and 72 h after carrageenan injection at doses of 12.5 and 25.0 mg/kg. Meanwhile, ROJ-ext markedly inhibited thrombosis induced by arterial-venous (AV) shunt (silk thread) in rats at doses of 6.25 and 12.5 mg/kg. Furthermore, ROJ-ext and one of its components, ruscogenin, significantly inhibited platelet aggregation induced by adenosine diphosphate (ADP) in rats by oral administration of 12.5 mg/kg or 0.7 mg/kg for three times, however, ophiopogonin D 1.4 mg/kg only showed slight inhibition. On the other hand, ophiopogonin D (0.5-2.0 mg/kg, p.o.) and ruscogenin (0.25-1.00 mg/kg, p.o.) produced dose-related inhibition of venous thrombosis induced by tight ligation of the inferior vena cava for 6 h in mice by once oral administration. The findings of this study indicate that an aqueous extract of Radix Ophiopogon japonicus (ROJ-ext) exerted significant antithrombotic activity and ruscogenin and ophiopogonin D are two of its active components, which supported its therapeutic use for thrombotic diseases.

[1]  Qiang Xu,et al.  Inhibitory effects of ethanol extract from Radix Ophiopogon japonicus on venous thrombosis linked with its endothelium-protective and anti-adhesive activities. , 2005, Vascular pharmacology.

[2]  Qiang Xu,et al.  Anti-inflammatory activities of aqueous extract from Radix Ophiopogon japonicus and its two constituents. , 2005, Biological & pharmaceutical bulletin.

[3]  R. Hirschelmann,et al.  Carrageenin-induced thrombosis in rats and mice: A model for testing antithrombotic substances? , 1985, Agents and Actions.

[4]  J. Bellón,et al.  In vitro mesothelialization of prosthetic materials designed for the repair of abdominal wall defects , 2003, Journal of materials science. Materials in medicine.

[5]  J. Herbert,et al.  Antithrombotic Properties of SSR182289A, a New, Orally Active Thrombin Inhibitor , 2003, Journal of Pharmacology and Experimental Therapeutics.

[6]  M. Choo,et al.  Antithrombotic and antiallergic activities of daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora. , 2002, Biological & pharmaceutical bulletin.

[7]  T. Murayama,et al.  Comparative studies on the constituents of ophiopogonis tuber and its congeners. VIII. Studies on the glycosides of the subterranean part of Ophiopogon japonicus Ker-Gawler cv. Nanus. , 1993, Chemical & pharmaceutical bulletin.

[8]  R. Peters,et al.  The Characterisation of Thrombus Development in an Improved Model of Arterio-Venous Shunt Thrombosis in the Rat and the Effects of Recombinant Desulphatohirudin (CGP 39393), Heparin, and lloprost , 1991, Thrombosis and Haemostasis.

[9]  J. Zhu,et al.  [Anti-arrhythmic effects and electrophysiological properties of Ophiopogon total saponins]. , 1990, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[10]  G. de Gaetano,et al.  Failure of aspirin at different doses to modify experimental thrombosis in rats. , 1980, Thrombosis research.

[11]  J. Shoji,et al.  Studies on the Constituents of Ophiopogonis Tuber. III. On the Structure of Ophiopogonin D , 1972 .

[12]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.